Friday, July 10, 2026

pharma · Migraine · Narcolepsy

H. Lundbeck A/S

H. Lundbeck A/S is a pharma organization headquartered in Valby, CN. Primary therapeutic focus areas include Migraine, Narcolepsy, Schizophrenia, Multiple System Atrophy, Chronic Migrane, Migrane, Medication Overuse Head

Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
Employees
112
Programs
17
Drugs
14
Patents
0
Clinical program

20433A

Phase 2 · other · Cushing's Disease

20433A for Cushing's Disease is a Phase 2 program (other) at H. Lundbeck A/S with 1 ClinicalTrials.gov record(s).

Internal code 20433A

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
H. Lundbeck A/S
Phase
Phase 2
Modality
other
Indication
Cushing's Disease
Status
active
Trials
1

Clinical trials